ERS International Congress, Madrid, 2019: highlights from the Airway Diseases, Asthma and COPD Assembly
- PMID: 32083111
- PMCID: PMC7024762
- DOI: 10.1183/23120541.00341-2019
ERS International Congress, Madrid, 2019: highlights from the Airway Diseases, Asthma and COPD Assembly
Abstract
The European Respiratory Society (ERS) International Congress 2019 in Madrid, Spain, was a platform for scientific discussion of the highest quality scientific research, cutting-edge techniques and innovative new therapies within the respiratory field. This article discusses some of the high-quality research studies presented at that Congress, with a focus on airway diseases, including asthma, COPD, small airways, bronchiectasis and cough, presented through the Airway Diseases, Asthma and COPD Assembly (Assembly 5) of the ERS. The authors establish the key take-home messages of these studies, compare their findings and place them into context of current understanding.
Copyright ©ERS 2020.
Conflict of interest statement
Conflict of interest: L. Lahousse reports society awards sponsored by AstraZeneca and Chiesi, and expert consultation for Boehringer Ingelheim GmbH and Novartis, outside the submitted work. Conflict of interest: T. Bahmer reports personal fees for lecturing and advice from Chiesi, GlaxoSmithKline, AstraZeneca, Novartis and Roche, outside the submitted work. Conflict of interest: S. Cuevas Ocaña has nothing to disclose. Conflict of interest: P. Flajolet has nothing to disclose. Conflict of interest: A.G. Mathioudakis has nothing to disclose. Conflict of interest: M. McDonnell has nothing to disclose. Conflict of interest: L. Uller has nothing to disclose. Conflict of interest: F. Schleich has nothing to disclose. Conflict of interest: S. Dortas Junior has nothing to disclose. Conflict of interest: M. Idzko has nothing to disclose. Conflict of interest: D. Singh reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Genentech, GlaxoSmithKline, Glenmark, Gossamerbio, Menarini, Mundipharma, Novartis, Peptinnovate, Pfizer, Pulmatrix, Theravance and Verona, outside the submitted work. Conflict of interest: F.LM. Ricciardolo has nothing to disclose. Conflict of interest: I.M. Adcock has nothing to disclose. Conflict of interest: O. Usmani reports grants and personal fees from AstraZeneca, Boehringer Ingelheim and Chiesi; personal fees from Aerocrine, Napp, Mundipharma, Sandoz, Takeda, Zentiva, Cipla and Pearl Therapeutics; and grants from GlaxoSmithKline, Prosonix and Edmond Pharma, all outside the submitted work. Conflict of interest: A. Spanevello has nothing to disclose. Conflict of interest: S.J. Bonvini has nothing to disclose.
References
-
- Ramos Ramirez P, Noreby M, Olsson HK, et al. Budesonide-induced decrease of IL-5 production does not affect allergen-induced bronchoconstriction or AHR in a novel guinea pig asthma model. Eur Respir J 2019; 54: Suppl. 63, PA4081.
-
- Bonvini SJ, Adcock JJ, Kobold NK, et al. A novel role for TRPM3 in Airway Smooth Muscle Contraction. Eur Respir J 2019; 54: Suppl. 63, OA4956.
Publication types
LinkOut - more resources
Full Text Sources